Til Stürmer, MD, MPH, PhD, FISPE

UNC Gillings School of Global Public Health
Chapel Hill, North Carolina, United States

My career as a medical researcher started with assessing the role of analgesics on kidney function and mortality, which culminated in a paper in the New England Journal of Medicine. After my formal training in epidemiology at Harvard School of Public Health, I continued pharmacoepidemiologic research with analyses of the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin on cognitive function, risk for colorectal cancer (CRC), and kidney function. Since 2003, I have focused on pharmacoepidemiology, developing and implementing methods to improve validity of nonexperimental research on the effects of medical interventions on clinically relevant outcomes based on real world data (mostly: US Medicare).
Since 2018, I am the Nancy A. Dreyer Distinguished Professor and Chair of the Department of Epidemiology, UNC Gillings School of Global Public Health. As former Director of the Center for Pharmacoepidemiology and Fellow and past President of ISPE, I have been able to assemble an outstanding inter-disciplinary team of researchers with expertise in epidemiology, pharmacoepidemiology, internal medicine, geriatrics, and biostatistics from within and outside of UNC to advance study design and analytic methods to provide valid evidence for relative benefit and harm of clinically relevant treatment alternatives in older adults. Funded by the National Institute on Aging (R01 AG023178, now R01 AG056479) since 2005, the research team published over 110 papers cited over 5,000 times focusing on developing and implementing novel methods to answer clinical questions of importance to older adults in the absence of alternative evidence.
For UNC's Clinical and Translational Science Award, NC TraCS, I continue to lead Comparative Effectiveness Research and Epidemiology as co-Director of Biostatistics, Epidemiology, and Research Design (BERD). CER/Epidemiology serves as the "front door" for nonexperimental research studies.

Novartis (Ownership Interest includes stock, stock options, patent or other intellectual property)Novo Nordisk (Ownership Interest includes stock, stock options, patent or other intellectual property, Research Grant includes principal investigator, collaborator or consultant and pending grants as well as grants already received)Roche (Ownership Interest includes stock, stock options, patent or other intellectual property)

Presentation(s):

• Intermediate Pharmacoepidemiology: Approaches to Unmeasured Confounders

  Thursday, August 25, 2022
  8:30 AM – 12:30 PM CEST

• Successful Implementation of Inverse-probability-of-screening Weights to Address Differential Outcome Screening: Effects of Statin Persistence on Breast Cancer Risk in Denmark

  Friday, August 26, 2022
  2:15 PM – 2:30 PM CEST

• Heterogeneous Treatment Effect of Glucagon-like Peptide 1 Receptor Agonists on Asthma/COPD exacerbation: Machine-learning Analysis of Two Nationwide Cohorts

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Translation of a Medicare Claims-based Frailty Index from International Classification of Diseases 9th Revision to 10th Revision

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Risk Ratios versus Hazard Ratios in Comparative Effectiveness Research: An Illustration Using Clinical Trial Data

  Friday, August 26, 2022
  2:00 PM – 2:15 PM CEST

• Alternative Analytic and Matching Approaches for the Prevalent New-user Design: A Simulation Study

  Friday, August 26, 2022
  6:00 PM – 6:15 PM CEST

• Advantages of Splitting Switchers and New Users in the Prevalent New User Design

  Friday, August 26, 2022
  6:30 PM – 6:45 PM CEST

• Using Iterative Causal Forest to Identify Heterogeneous Treatment Effects: Sodium-glucose Cotransporter-2 inhibitors versus Glucagon-like Peptide-1 Receptor Agonists on Hospitalization for Heart Failure

  Sunday, August 28, 2022
  9:45 AM – 10:00 AM CEST

• Hot Topic Session: How Can We Mitigate Publication of Poorly Conducted RWE Studies? Keynote Session [Plenary]

  Sunday, August 28, 2022
  3:15 PM – 4:45 PM CEST